Derm News: 2007.24(1)

Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma

Journal of the American Academy of Dermatology, 56(4):584-587
Jacob A. Sepmeyer, John P. Greer, Tatsuki Koyama, John A. Zic
ABSTRACT

Four patients with stable or progressive cutaneous T-cell lymphoma treated with oral bexarotene received oral rosiglitazone. After 16 weeks of combination therapy, skin score decreased in two patients. Pruritus was alleviated in 3 of 4 patients, whereas quality of life was unchanged. Adverse events included hyperlipidemia, anemia, neutropenia, and lymphopenia.

    Back to Current Volume:   Dermatology News 2007.24

The Derm News service provided by the Editorial Consultants of Skin Therapy Letter^© and its founding editor Dr. Stuart Maddin.